Back to top
more

KALA BIO, Inc. (KALA)

(Delayed Data from NSDQ)

$6.90 USD

6.90
8,538

+0.19 (2.79%)

Updated May 10, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.

Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?

Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More

Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.

Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?

Is (KALA) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for May 26th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 26th

Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?

Is (KALA) Outperforming Other Medical Stocks This Year?

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.

Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Kala Pharmaceuticals' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.

Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?

Is (KALA) Outperforming Other Medical Stocks This Year?

Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals

The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals

Zacks.com featured highlights include: Kala Pharmaceuticals, Unicharm and Capcom

Zacks.com featured highlights include: Kala Pharmaceuticals, Unicharm and Capcom